B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature

Cells, Journal Year: 2025, Volume and Issue: 14(7), P. 530 - 530

Published: April 2, 2025

B7-H3 (CD276), a member of the B7 immune checkpoint family, plays critical role in modulating responses and has emerged as promising target cancer therapy. It is highly expressed various malignancies, where it promotes tumor evasion from T cell surveillance contributes to progression, metastasis, therapeutic resistance, showing correlation with poor prognosis patients. Although its receptors were not fully identified, signaling involves key intracellular pathways, including JAK/STAT, NF-κB, PI3K/Akt, MAPK, driving processes crucial for supporting growth such proliferation, invasion, apoptosis inhibition. Beyond modulation, influences metabolism, angiogenesis, epithelial-to-mesenchymal transition, further exacerbating aggressiveness. The development B7-H3-targeting therapies, monoclonal antibodies, antibody–drug conjugates, CAR-T cells, offers avenues treatment. This review provides an up-to-date summary B7H3 mechanisms action, putative receptors, ongoing clinical trials evaluating therapies targeting B7H3, focusing on molecule’s gastrointestinal tumors.

Language: Английский

B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review

Journal of Immunotherapy and Precision Oncology, Journal Year: 2025, Volume and Issue: 8(2), P. 153 - 160

Published: April 10, 2025

ABSTRACT B7 homolog 4 (B7-H4) is a transmembrane protein found on immune cells and frequently overexpressed in various solid tumors, making it promising target for cancer therapy. B7-H4–directed agents, particularly antibody-drug conjugates (ADCs) like puxitatug samrotecan (AZD8205), felmetatug vedotin (SGN-B7H4V), GSK5733584, have demonstrated early clinical activity with response rates triple-negative breast (TNBC). Combination strategies, such as ADCs anti–PD-1 or PARP inhibitor therapies, also shown enhanced tumor regression preclinical models are the subject of several ongoing trials. This review highlights current landscape B7-H4–targeted their progress trials, potential combination approaches to improve outcomes B7-H4–expressing cancers.

Language: Английский

When Impact Multiplies: Defining Trials and Insights From 2025 SGO Annual Meeting

International Journal of Gynecological Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 101895 - 101895

Published: April 1, 2025

"When Impact Multiplies: Defining Trials and Insights From the 2025 Society of Gynecologic Oncology Annual Meeting" features most significant potentially practice-changing research presented at Meeting on Women's Cancer. Held in Seattle, WA from March 14 to 17, 2025, remains one premier conferences for professionals dedicated advancing gynecologic cancer care. The scientific program covered a broad spectrum topics across oncology, highlighting latest advancements research, clinical practice, patient-centered this comprehensive program, we selected studies considered be highly impactful.

Language: Английский